Skip to Content

HemaCare Corporation (Other OTC: HEMA)

Merger

  • Date:
  • 12/16/2019
  • Company Name:
  • HemaCare Corporation
  • Stock Symbol:
  • HEMA
  • Company Name - Buyer:
  • Charles River Laboratories International, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 12/16/2019

Case Finder

Locate any case using the tools below.

NEW YORK, December 16, 2019 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of HemaCare Corporation (Other OTC: HEMA) breached their fiduciary duties or violated the federal securities laws in connection with the company’s proposed sale to Charles River Laboratories International, Inc.

On December 16, 2019, HemaCare announced that it had signed an agreement to be acquired by Charles River for $25.40 per share in cash, or a total of approximately $380 million. The deal is scheduled to close in the first quarter of 2020. Bragar Eagel & Squire is concerned that HemaCare’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for HemaCare stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in HemaCare Corporation . BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: